Neuroprotective effect of SGLT2 inhibitors.
Open accessThe DOI matches its Crossref record; 122 of the 124 references it cites were found in a registry or an index; 21 of the 97 sources its claims cite were checked for support.
Abstract
Patients with diabetes are at higher risk of cardiovascular diseases and cognitive impairment. SGLT2 inhibitors (Empagliflozin, Canagliflozin, Dapagliflozin, Ertugliflozin, Sotagliflozin) are newer hypoglycemic agents with many pleiotropic effects. In this review, we discuss their neuroprotective potential. SGLT2 inhibitors (SGLT2i) are lipid-soluble and reach the brain/serum ratio from 0.3 to 0.5. SGLT receptors are present in the central nervous system (CNS). Flozins are not fully SGLT2-selective and have an affinity for the SGLT1 receptor, which is associated with protection against ischemia/reperfusion brain damage. SGLT2i show an anti-inflammatory and anti-atherosclerotic effect, including reduction of proinflammatory cytokines, M2 macrophage polarization, JAK2/STAT1 and NLRP3 inflammasome inhibition, as well as cIMT regression. They also mitigate oxidative stress. SGLT2i improve endothelial function, prevent remodeling and exert a protective effect on the neurovascular unit, blood-brain barrier, pericytes, astrocytes, microglia, and oligodendrocytes. Flozins are also able to inhibit AChE, which contributes to cognitive improvement. Empagliflozin significantly increases the level of cerebral BDNF, which modulates neurotransmission and ensures growth, survival, and plasticity of neurons. Moreover, they may be able to restore the circadian rhythm of mTOR activation, which is quite a novel finding in the field of research on metabolic diseases and cognitive impairment. SGLT2i have a great potential to protect against atherosclerosis and cognitive impairment in patients with type 2 diabetes mellitus.
Overview
CoChat Summary
TL;DR
This narrative review summarizes proposed neuroprotective mechanisms of SGLT2 inhibitors in type 2 diabetes, atherosclerosis, and cognitive impairment, including anti-inflammatory, antioxidant, anti-atherosclerotic, AChE-inhibiting, BDNF-increasing, and mTOR-rhythm-restoring effects. It concludes that flozins have potential but that long-term clinical trials are needed to establish clinical relevance.
Key findings
- SGLT2 inhibitors are lipid-soluble and cross the blood-brain barrier, with brain/serum AUC ratios of 0.3 for canagliflozin and dapagliflozin and 0.5 for empagliflozin; SGLT1/SGLT2 are expressed in the CNS, and SGLT1 inhibition is linked to protection against ischemia/reperfusion brain damage.
- Anti-inflammatory and anti-atherosclerotic effects include reduced proinflammatory cytokines, M2 macrophage polarization, JAK2/STAT1 and NLRP3 inflammasome inhibition, and cIMT regression; empagliflozin reduced cIMT by 7.9% (p < 0.0001) after 3 months, and canagliflozin lowered IL-6 by 26.6% (p = 0.010) after 2 years.
- AChE inhibition may contribute to cognitive improvement: canagliflozin Ki = 0.12859 µM with estimated brain concentration ~3 µM, enough to inhibit AChE; empagliflozin Ki = 0.177 µM with brain concentration 0.5 µM, also enough; dapagliflozin Ki = 25.02 µM with brain concentration 0.3 µM, not enough.
- Empagliflozin significantly increased cerebral BDNF in db/db mice and improved cognition; in rat cerebral ischemia/reperfusion, empagliflozin dose-dependently reduced neuronal death, infarct size, and cognitive impairment via HIF-1α/VEGF signaling; SGLT2i may restore circadian mTOR activation and mimic fasting.
Methods
- Narrative review; no primary data collection or systematic search strategy is described.
- Evidence synthesized includes preclinical studies (murine/rat models, ex vivo, in silico) and selected clinical studies on SGLT2 inhibitors, atherosclerosis, inflammation, oxidative stress, mTOR signaling, cerebrovascular dysfunction, and Alzheimer’s disease pathology.
- Main analysis is a qualitative synthesis of mechanisms and reported outcomes, with one ongoing clinical trial noted: dapagliflozin in Alzheimer’s disease (NCT03801642).
Limitations
- The paper states that long-term clinical trials are necessary to establish whether the discussed mechanisms are clinically relevant, since atheroprotective and neuroprotective effects will not be immediate and require long-term SGLT2i intake.
- The paper notes that there is no available data on adverse CNS effects of flozins and that the exact mechanism of cardiovascular benefit has not been fully established.
- Evident from the text: this is a narrative review without systematic methods, and many key findings come from animal, ex vivo, or in silico studies, with limited human cognitive-outcome data.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
14 Valid · 1 Not valid · 67 Not checked · 11 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Canagliflozin, Dapagliflozin, Sotagliflozin significantly decrease the composed primary end-point, including cardiovascular mortality and other cardiovascular outcomes [10,11,12].”
§ Neuroprotective Effect of SGLT2 Inhibitors > 1. Introduction
What the sources say
- Supportedcites [10] Mahaffey, 2018, Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results from the CANVAS Program (Canagliflozin Cardiovascular Assessment Study), Circulation source
The Methods (Outcomes) define the composite endpoint as cardiovascular mortality, nonfatal myocardial infarction, or nonfatal stroke. The Results report that canagliflozin significantly reduced that endpoint versus placebo (P=0.02 for superiority). In this sentence with three citations, this source supports the canagliflozin portion; it is not offered as evidence for the other two drugs. (LLM, conf=0.93)
- Partly supportedcites [11] Wiviott, 2019, Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes, N. Engl. J. Med. sourceExperimental — accuracy not yet measured
The Cardiovascular and Renal Outcomes section reports that dapagliflozin significantly reduced the composite of cardiovascular death or hospitalization for heart failure. It also says the reduction was driven by fewer heart-failure hospitalizations, with no difference in cardiovascular death; MACE was not significantly reduced. This paper tests dapagliflozin, not the other two drugs named alongside it. Page numbers were not supplied in the passages. (LLM, conf=0.89)
- Supportedcites [12] Bhatt, 2021, Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure, N. Engl. J. Med. source
The Methods (p. 2) define the sotagliflozin trial’s composite primary endpoint as cardiovascular death, heart-failure hospitalization, and urgent heart-failure visits. The Efficacy End Points (p. 7) report a significantly lower rate for that composite with sotagliflozin than with placebo (hazard ratio 0.67; P<0.001). This source supports the sotagliflozin portion of the multi-citation sentence; it does not establish a significant reduction in cardiovascular death on its own. (LLM, conf=0.92)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“SGLT1 inhibitors are present in the pyramidal cells of the brain cortex, Purkinje cerebellum cells, hippocampus pyramidal, and granular cells [20].”
§ Neuroprotective Effect of SGLT2 Inhibitors > 2. Neurological Potential of SGLT2 Inhibitors
What the sources say
- Partly supportedcites [20] Poppe, 1997, Expression of the Na+-D-glucose cotransporter SGLT1 in neurons, J. Neurochem. sourceExperimental — accuracy not yet measured
The 'Expression of SGLT1 protein in brain' section and Fig. 7 report SGLT1 protein in cortical pyramidal cells, hippocampal pyramidal and granular cells, and cerebellar Purkinje cells. The citing sentence says 'SGLT1 inhibitors' are present; these passages identify the protein, not inhibitors. (LLM, conf=0.88)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources that could be checked couldn’t confirm or dispute this claim.
In the paper
“Among commonly used SGLT2 inhibitors, Canagliflozin has the greatest potential for inhibiting SGLT1 receptors.”
§ Neuroprotective Effect of SGLT2 Inhibitors > 2. Neurological Potential of SGLT2 Inhibitors
What the sources say
- Could not verifycites [27] Malhotra, 2015, Sodium glucose co-transporter inhibitors—A new class of old drugs, Int. J. Appl. Basic Med. Res. sourceExperimental — accuracy not yet measured
Our copy names canagliflozin only as 'the prototype drug among the newer agents' with its pharmacokinetics (PHARMACOKINETICS section), and it discusses SGLT-1/SGLT-2 selectivity in general terms (INTRODUCTION, HISTORICAL BACKGROUND, 'On fasting hypoglycemia'), but nowhere states that canagliflozin has the greatest SGLT-1 inhibitory potential among the SGLT2 inhibitors. The one place that could carry it — 'Table 1 New SGLT inhibitors and their status and selectivity' — appears in our copy only as a caption, with no table rows/indexed content, so the comparative selectivity data are not available to us. Searches for 'canagliflozin SGLT1 selectivity', 'selectivity ratio SGLT-1 versus SGLT-2 / IC50', 'Table 1 status and selectivity', and 'SGLT-1 inhibition adverse effects' returned no passage making or contradicting the claim. (LLM, conf=0.65)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In humans, the serum level of IL-6 dropped by 26.6% (p = 0.010) after 2 years of canagliflozin treatment [35].”
§ Neuroprotective Effect of SGLT2 Inhibitors > 4. Inflammation
What the sources say
- Partly supportedcites [35] Heerspink, 2019, Canagliflozin reduces inflammation and fibrosis biomarkers: A potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease, Diabetologia sourceExperimental — accuracy not yet measured
The Abstract (Results) and Table 2 of our copy do carry the exact figure: canagliflozin 300 mg/day lowered IL-6 by 26.6% (95% CI −42.0, −7.2), p = 0.010, over 2 years (104 weeks) — but explicitly as a least-squares mean percentage DIFFERENCE VERSUS GLIMEPIRIDE and only at the 300 mg dose (100 mg gave −26.3%, p = 0.011), in people with type 2 diabetes and elevated albuminuria (CANTATA-D/SU subset, n = 296). The citing sentence recasts this between-group contrast as an absolute 'drop' of 26.6% from canagliflozin treatment alone, and drops both the comparator and the dose qualifiers. It also says 'serum', whereas the Methods (Biomarker measurement) state IL-6 was measured by Luminex assay on stored PLASMA samples. The magnitude, p value and 2-year duration are faithful; the attribution of the 26.6% as a within-treatment fall in serum is not supported. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In previous studies, atherosclerotic lesions in intra- and extra-cranial arteries were associated with cognitive impairment and even dementia [2,66,67].”
§ Neuroprotective Effect of SGLT2 Inhibitors > 3. Atherosclerosis, Cognitive Impairment, and SGLT2i
What the sources say
- Not checked yetcites [2] Dearborn, 2017, Intracranial atherosclerosis and dementia The Atherosclerosis Risk in Communities (ARIC) Study, Am. Acad. Neurol.
- Supportedcites [66] Bos, 2015, Atherosclerotic calcification is related to a higher risk of dementia and cognitive decline, Alzheimer’s Dement. source
The Results section reports that after censoring for stroke, 'both extracranial and intracranial carotid artery calcification remained statistically significantly associated with dementia' (HR 1.32 and 1.34 per SD increase), and that larger calcification volumes were associated with cognitive decline in nondemented persons. The Abstract Conclusions and Discussion (generalized atherosclerosis 'is associated with dementia') state the same association for dementia and cognitive deterioration, matching the cited claim for both intra- and extra-cranial arteries. Minor wording differences (calcification as the atherosclerosis measure; 'cognitive decline' rather than 'cognitive impairment') do not alter the attributed content. (LLM, conf=0.88)
- Partly supportedcites [67] Wingo, 2020, Shared proteomic effects of cerebral atherosclerosis and Alzheimer’s disease on the human brain, Nat. Neurosci. sourceExperimental — accuracy not yet measured
The Abstract/Introduction of our copy supports the intracranial half of the claim: cerebral atherosclerosis is defined as plaques in 'the walls of large arteries in the brain' and is stated to be among the earliest changes associated with development of AD dementia, with ~three times higher risk for AD and nine times higher risk for vascular dementia (Abstract, p. 1). The METHODS confirm the paper's own atherosclerosis assessment covered only intracranial vessels — visual grading of the Circle of Willis (vertebral, basilar, posterior, middle and anterior cerebral arteries and proximal branches), not extracranial arteries (METHODS, ROS/MAP section). No passage in our copy addresses atherosclerotic lesions in extra-cranial arteries and cognition (searched: 'extracranial carotid atherosclerosis', 'carotid artery atherosclerosis systemic extracranial vessels'), so that part of the citing sentence is not supported by this source. (LLM, conf=0.72)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
42 more claims · 2 with their cited sources checked
Create a free account to see all 93 claims and to verify the 76 references still open.
- It may state two separate claims as one. 41
- Probably not a substantial claim. 6
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, SGLT2is have demonstrated neuroinflammatory and antioxidative effects in addition to cardiovascular prevention.56”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [56]
Citations
Cites
1 retracted
Xue, L., Yuan, X., Zhang, S., & Zhao, X. (2021) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2021/9388562 · Cited by 20
RetractedEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482 · cited 1×
“In the CANTOS study, inhibition of interleukin-1β with canakinumab significantly reduced cardiovascular risk independently of lipid levels [78].”
BackgroundDapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F.-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2024816 · Cited by 5,618 · cited 1×
“The exact mechanism has not been fully established yet, and SGLT2 inhibitors show many additional beneficial effects which contribute to their wider use, even in non-diabetic patients [14].”
BackgroundReactive Oxygen Species in Inflammation and Tissue Injury
Mittal, M., Siddiqui, M. R., Tran, K., Reddy, S. P., & Malik, A. B. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2012.5149 · Cited by 4,897 · cited 4×
“The overproduction of ROS or decrease in the anti-oxidant defense results in oxidative stress, which is a significant contributor to vascular diseases, including atherosclerosis, as it causes endothelial dysfunction, promotes remodeling and further enhances inflammation [94].”
BackgroundInfluentialO'Leary, D. H., Polak, J. F., Kronmal, R. A., Manolio, T. A., Burke, G. L., & Wolfson, S. K. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901073400103 · Cited by 4,685
The NLRP3 Inflammasome: an overview of mechanisms of activation and regulation
Kelley, N., Jeltema, D., Duan, Y., & He, Y. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133328 · Cited by 3,539 · cited 1×
“It is a crucial element of the innate immune system activated not only by microbial infection or cellular damage but also by chronic inflammatory diseases, including atherosclerosis and Alzheimer’s disease [80].”
BackgroundEinarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0728-6 · Cited by 2,312 · cited 1×
“Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease causing a variety of complications, including atherosclerosis which is associated with increased cardiovascular risk contributing to reduced life expectancy [1].”
BackgroundSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868 · cited 1×
“It is even called a “dual SGLT1/SGLT2 inhibitor”, however, it is the newest Flozin, and it is not yet used in diabetic patients on a large scale [12].”
BackgroundAlzheimer's disease: Targeting the Cholinergic System
H. Ferreira-Vieira, T., M. Guimaraes, I., R. Silva, F., & M. Ribeiro, F. (2016) · Current Neuropharmacology · doi:10.2174/1570159x13666150716165726 · Cited by 1,551 · cited 1×
“Patients with Alzheimer’s disease have a reduced amount of acetylcholine neurotransmitters in the brain, and acetylcholinesterase inhibitors including donepezil, rivastigmine, galantamine are commonly used to increase the acetylcholine level and improve cognition [61].”
BackgroundCardiovascular outcomes with ertugliflozin in type 2 diabetes
Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2004967 · Cited by 1,514 · cited 1×
“placebo in reducing cardiovascular mortality and other cardiovascular outcomes [13].”
BackgroundBiology of Human Sodium Glucose Transporters
Wright, E. M., Loo, D. D. F., & Hirayama, B. A. (2011) · Physiological Reviews · doi:10.1152/physrev.00055.2009 · Cited by 1,430 · cited 1×
“SGLT1 transports two Na+ ions with one D-glucose molecule and SGLT2 one sodium ion with one D-glucose [19].”
BackgroundBrain-derived neurotrophic factor and its clinical Implications
Bathina, S., & Das, U. N. (2015) · Archives of Medical Science · doi:10.5114/aoms.2015.56342 · Cited by 1,381 · cited 1×
“It is an important factor for the processes of learning and memorizing [63].”
BackgroundRole of pro-inflammatory cytokines released from microglia in Alzheimer's disease.
(2015) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2305-5839.2015.03.49 · Cited by 1,288 · cited 1×
“M1 activated microglia impair NVU by secreting proinflammatory cytokines, including TNF-α, IL-1β, IL-6, IL-18, which contribute to neurodegeneration by breaking neurotransmitters into bioactive metabolites, tau hyperphosphorylation, β-amyloid oligomerization, and complement activation [76,77].”
BackgroundRole of oxidative stress in Alzheimer’s disease
HUANG, W.-J., ZHANG, X., & CHEN, W.-W. (2016) · Biomedical Reports · doi:10.3892/br.2016.630 · Cited by 1,023
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
(2016) · New England Journal of Medicine · doi:10.1056/nejmc1600827 · Cited by 700 · cited 1×
“As it has been proved by large doubleblind clinical trials, Empagliflozin not only decreases HbA1c in diabetic patients but also improves their life expectancy by reducing cardiovascular mortality [9].”
BackgroundPost-stroke cognitive impairment: epidemiology, mechanisms and management.
(2014) · PubMed Central · doi:10.3978/j.issn.2305-5839.2014.08.05 · Cited by 680
Macrophages in Atherosclerosis Regression
Barrett, T. J. (2020) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312802 · Cited by 628
Glucose transporters in brain in health and disease
Koepsell, H. (2020) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-020-02441-x · Cited by 558 · cited 2×
“The presence of SGLT1/SGLT2 was also described in the abluminal membrane of the capillary endothelium [21].”
BackgroundKim, S. R., Lee, S.-G., Kim, S. H., Kim, J. H., Choi, E., Cho, W., Rim, J. H., Hwang, I., Lee, C. J., Lee, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15983-6 · Cited by 536 · cited 2×
“NLRP3 Inflammasome Inhibition n/a n/a Yes [39] Yes [40] n/a”
BackgroundAn update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus
Hsia, D. S., Grove, O., & Cefalu, W. T. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000311 · Cited by 508 · cited 1×
“Their main mechanism of action is inhibiting SGLT2 receptors in the proximal tubules of the kidneys and thus lowering blood glucose levels by blocking its reabsorption from the urine [8].”
Mahaffey, K. W., Neal, B., Perkovic, V., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Fabbrini, E., Sun, T., Li, Q., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032038 · Cited by 498
Heerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A., & Mayer, G. (2019) · Diabetologia · doi:10.1007/s00125-019-4859-4 · Cited by 457 · cited 3×
“Anti-inflammatory n/a Yes [35] Yes [36] Yes [37] No|n/a [38] Figure 1.”
BackgroundLin, B., Koibuchi, N., Hasegawa, Y., Sueta, D., Toyama, K., Uekawa, K., Ma, M., Nakagawa, T., Kusaka, H., & Kim-Mitsuyama, S. (2014) · Cardiovascular Diabetology · doi:10.1186/s12933-014-0148-1 · Cited by 423 · cited 1×
“Moreover, this effect was accompanied by improvement in cognitive functions [31].”
Type 3 Diabetes and Its Role Implications in Alzheimer’s Disease
Nguyen, T. T., Ta, Q. T. H., Nguyen, T. K. O., Nguyen, T. T. D., & Van Giau, V. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21093165 · Cited by 393 · cited 1×
“Glucose metabolism is also impaired in Alzheimer’s disease, as it is sometimes called ‘Type 3 diabetes’ or ‘diabetes of the brain’ [5].”
BackgroundAn updated meta-analysis of cohort studies: Diabetes and risk of Alzheimer’s disease
Zhang, J., Chen, C., Hua, S., Liao, H., Wang, M., Xiong, Y., & Cao, F. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.10.024 · Cited by 376
Ye, Y., Bajaj, M., Yang, H.-C., Perez-Polo, J. R., & Birnbaum, Y. (2017) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-017-6725-2 · Cited by 368 · cited 1×
“NLRP3 Inflammasome Inhibition n/a n/a Yes [39] Yes [40] n/a”
BackgroundGSK3 and tau: Two convergence points in Alzheimer’s disease
Hernandez, F., Lucas, J. J., & Avila, J. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2012-129025 · Cited by 359
Systemic inflammation impairs microglial Aβ clearance through NLRP3 inflammasome
Tejera, D., Mercan, D., Sanchez‐Caro, J. M., Hanan, M., Greenberg, D., Soreq, H., Latz, E., Golenbock, D., & Heneka, M. T. (2019) · The EMBO Journal · doi:10.15252/embj.2018101064 · Cited by 351 · cited 1×
“In Alzheimer’s disease, NLRP3 inflammasome links systemic inflammation with neuroinflammation and impairs the removal of amyloid-beta by the microglia [83].”
BackgroundFaraco, G., Sugiyama, Y., Lane, D., Garcia-Bonilla, L., Chang, H., Santisteban, M. M., Racchumi, G., Murphy, M., Van Rooijen, N., Anrather, J., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86950 · Cited by 350 · cited 1×
“Macrophages take part in cognitive impairment as perivascular macrophages (PVM) are the source of vascular oxidative stress by producing a large amount of free radicals near the neurovascular unit [90].”
Backgroundvan der Heijden, T., Kritikou, E., Venema, W., van Duijn, J., van Santbrink, P. J., Slütter, B., Foks, A. C., Bot, I., & Kuiper, J. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.309575 · Cited by 348 · cited 1×
“In a mouse model of atherosclerosis, the inhibition of the NLRP3 inflammasome by MCC950 resulted in a significant reduction in atherosclerotic lesions [82].”
BackgroundThe role of cytokines in the development of atherosclerosis
Fatkhullina, A. R., Peshkova, I. O., & Koltsova, E. K. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916110134 · Cited by 323 · cited 3×
“There is abundant evidence from animal studies showing that SGLT2 inhibitors slow down the progression of atherosclerosis and exert an anti-inflammatory effect by reducing the expression of proinflammatory cytokines, including TNF-α, IL-1β, IL-6, MCP-1, ICAM, VCAM [69].”
BackgroundInfluentialHypertension and Stroke: Update on Treatment
Wajngarten, M., & Silva, G. S. (2019) · European Cardiology Review · doi:10.15420/ecr.2019.11.1 · Cited by 304
Lonnemann, N., Hosseini, S., Marchetti, C., Skouras, D. B., Stefanoni, D., D’Alessandro, A., Dinarello, C. A., & Korte, M. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2009680117 · Cited by 298 · cited 1×
“This effect may be clinically significant, as, in another study, the inhibition of NLRP3 by OLT1177 significantly improved cognitive impairment in a mouse model of Alzheimer’s disease [84].”
ResultRole of mTOR in Glucose and Lipid Metabolism
Mao, Z., & Zhang, W. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19072043 · Cited by 296 · cited 1×
“Chronic up-regulation of mTOR is present in an anabolic state (increased levels of glucose, amino acids, growth factors) associated with over-nutrition and lack of physical activity [101].”
BackgroundThe role of glucose transporters in brain disease: Diabetes and Alzheimer’s disease
Shah, K., DeSilva, S., & Abbruscato, T. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131012629 · Cited by 288 · cited 1×
“SGLTs are responsible for the transport of glucose, galactose and sodium ions against the concentration gradients [18].”
BackgroundSystemic inflammation during midlife and cognitive change over 20 years: The ARIC Study
Walker, K. A., Gottesman, R. F., Wu, A., Knopman, D. S., Gross, A. L., Mosley, T. H., Selvin, E., & Windham, B. G. (2019) · Neurology · doi:10.1212/wnl.0000000000007094 · Cited by 282 · cited 1×
“, elevated inflammatory markers in middle adulthood resulted in significant cognitive decline after 20 years [74].”
BackgroundLangbaum, J. B. S., Chen, K., Lee, W., Reschke, C., Bandy, D., Fleisher, A. S., Alexander, G. E., Foster, N. L., Weiner, M. W., Koeppe, R. A., et al. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2008.12.072 · Cited by 279
Sa-nguanmoo, P., Tanajak, P., Kerdphoo, S., Jaiwongkam, T., Pratchayasakul, W., Chattipakorn, N., & Chattipakorn, S. C. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.08.005 · Cited by 274
Understanding the Role of Systemic Inflammation in Alzheimer’s Disease
Walker, K. A., Ficek, B. N., & Westbrook, R. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00333 · Cited by 259 · cited 2×
“In the central nervous system, M1 polarization of glial cells was associated with neurodegeneration [73].”
BackgroundMitochondria as Potential Targets in Alzheimer Disease Therapy: An Update
Cenini, G., & Voos, W. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00902 · Cited by 257 · cited 1×
“Cascade hypothesis” in Alzheimer’s Disease pathology [98].”
Cardiovascular risk assessment in patients with diabetes
Bertoluci, M. C., & Rocha, V. Z. (2017) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-017-0225-1 · Cited by 255
The blood–brain barrier endothelium: a target for pro-inflammatory cytokines
Rochfort, K. D., & Cummins, P. M. (2015) · Biochemical Society Transactions · doi:10.1042/bst20140319 · Cited by 245 · cited 1×
“Systemic inflammation is associated with circulating proinflammatory cytokines, which impair the endothelium of brain microvessels, increase the permeability of the blood-brain barrier and change the phenotype of astrocytes and microglia into pro-inflammatory ones [75].”
BackgroundExalto, L. G., Biessels, G. J., Karter, A. J., Huang, E. S., Katon, W. J., Minkoff, J. R., & Whitmer, R. A. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70048-2 · Cited by 244 · cited 1×
“Among diabetics, the presence of micro- and macrovascular complications increases the risk of cognitive decline even further, suggesting that vascular mechanisms, including atherosclerosis, are important players [7].”
BackgroundThe rat blood-brain barrier transcriptome
Enerson, B. E., & Drewes, L. R. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600249 · Cited by 205 · cited 3×
“Brain expression of SGLT2 is lower than SGLT1, and it occurs mainly in the microvessels of the blood-brain barrier, but also in the amygdala, hypothalamus, periaqueductal gray (PAG), and in the dorsomedial medulla – the nucleus of the solitary tract (NTS) [22,23].”
BackgroundSabia, S., Fayosse, A., Dumurgier, J., Schnitzler, A., Empana, J.-P., Ebmeier, K. P., Dugravot, A., Kivimäki, M., & Singh-Manoux, A. (2019) · BMJ · doi:10.1136/bmj.l4414 · Cited by 205 · cited 1×
“show that cardiovascular health at the age of 50 years is crucial for further development of cognitive impairment [68].”
BackgroundIntersection of pathological tau and microglia at the synapse
Vogels, T., Murgoci, A.-N., & Hromádka, T. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0754-y · Cited by 197
Anthony (2006) · doi:10.2337/db06-0376 · Cited by 195
Sun, X., Han, F., Lu, Q., Li, X., Ren, D., Zhang, J., Han, Y., Xiang, Y. K., & Li, J. (2020) · Diabetes · doi:10.2337/db19-0991 · Cited by 193 · cited 1×
“Reduced mTOR Signaling n/a Yes [51] Yes [51] Yes [52] Yes [53]”
BackgroundKhacho, M., Clark, A., Svoboda, D. S., MacLaurin, J. G., Lagace, D. C., Park, D. S., & Slack, R. S. (2017) · Human Molecular Genetics · doi:10.1093/hmg/ddx217 · Cited by 192 · cited 1×
“In a murine model, depletion of AIF (apoptosis-inducing factor), which is a mitochondrial protein taking part in apoptosis and electron transport chain, was associated with serious disturbances in hippocampal-dependant spatial learning and memory [99].”
BackgroundNeurovascular Dysfunction in Vascular Dementia, Alzheimer's and Atherosclerosis
Shabir, O., Berwick, J., & Francis, S. E. (2018) · BMC Neuroscience · doi:10.1186/s12868-018-0465-5 · Cited by 191
The Effects of SGLT2 Inhibitors on Lipid Metabolism
Szekeres, Z., Toth, K., & Szabados, E. (2021) · Metabolites · doi:10.3390/metabo11020087 · Cited by 187 · cited 1×
“It may be associated with a similar effect of glucose fasting-like metabolic switch as the one observed in ketogenic diets, which in some circumstances also improve brain seizure activity [54].”
BackgroundZhou, J., Zhu, J., Yu, S.-J., Ma, H.-L., Chen, J., Ding, X.-F., Chen, G., Liang, Y., & Zhang, Q. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110821 · Cited by 182 · cited 1×
“Reduced mTOR Signaling n/a Yes [51] Yes [51] Yes [52] Yes [53]”
BackgroundHierro-Bujalance, C., Infante-Garcia, C., del Marco, A., Herrera, M., Carranza-Naval, M. J., Suarez, J., Alves-Martinez, P., Lubian-Lopez, S., & Garcia-Alloza, M. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00607-4 · Cited by 181 · cited 2×
“This effect was associated with the improvement in cognitive functions, including memory and learning processes in the new object discrimination test and Morris water maze test [15].”
BackgroundMethodSodium—Glucose cotransporter inhibitors and oxidative stress: An update
Yaribeygi, H., Atkin, S. L., Butler, A. E., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.26760 · Cited by 167 · cited 1×
“Interestingly, SGLT2 inhibitors were proven to ameliorate oxidative stress not only by maintaining a normal glucose level but also by reducing the generation of free radicals (Table 1) [97].”
BackgroundIannantuoni, F., M. de Marañon, A., Diaz-Morales, N., Falcon, R., Bañuls, C., Abad-Jimenez, Z., Victor, V. M., Hernandez-Mijares, A., & Rovira-Llopis, S. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8111814 · Cited by 166
Shared proteomic effects of cerebral atherosclerosis and Alzheimer’s disease on the human brain
Wingo, A. P., Fan, W., Duong, D. M., Gerasimov, E. S., Dammer, E. B., Liu, Y., Harerimana, N. V., White, B., Thambisetty, M., Troncoso, J. C., et al. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0635-5 · Cited by 161 · cited 2×
“, CA was associated with reduced synaptic function, excess myelination, and axonal injury independently of ischemia [67].”
BackgroundUsman, M. S., Siddiqi, T. J., Memon, M. M., Khan, M. S., Rawasia, W. F., Talha Ayub, M., Sreenivasan, J., & Golzar, Y. (2018) · European Journal of Preventive Cardiology · doi:10.1177/2047487318755531 · Cited by 160
Novel Insights Into the NLRP3 Inflammasome in Atherosclerosis
Jin, Y. H., & Fu, J. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012219 · Cited by 160
Liu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155 · cited 4×
“There is abundant evidence from animal studies showing that SGLT2 inhibitors slow down the progression of atherosclerosis and exert an anti-inflammatory effect by reducing the expression of proinflammatory cytokines, including TNF-α, IL-1β, IL-6, MCP-1, ICAM, VCAM [69].”
BackgroundInfluentialAtherosclerosis and Alzheimer - diseases with a common cause? Inflammation, oxysterols, vasculature
Lathe, R., Tsitrina, A. A., & Kotelevtsev, Y. V. (2014) · BMC Geriatrics · doi:10.1186/1471-2318-14-36 · Cited by 149 · cited 1×
“They are also an important factor in the pathology of cognitive impairment associated with Alzheimer’s disease as their infiltration is increased in patients with AD being most abundant in the brain regions rich in Aβ plaques [85].”
BackgroundTahara, A., Takasu, T., Yokono, M., Imamura, M., & Kurosaki, E. (2016) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2016.02.003 · Cited by 148 · cited 10×
“SGLT2 inhibitors can possibly bring benefits in patients with Alzheimer’s Disease using the abovementioned mechanisms, including not only anti-inflammatory, antioxidative or atheroprotective effects, but also direct neuroprotective effects including BDNF increase and AChE inhibition.”
BackgroundInfluentialOxidative stress predicts cognitive decline with aging in healthy adults: an observational study
Hajjar, I., Hayek, S. S., Goldstein, F. C., Martin, G., Jones, D. P., & Quyyumi, A. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1026-z · Cited by 143
Atherosclerotic calcification is related to a higher risk of dementia and cognitive decline
Bos, D., Vernooij, M. W., de Bruijn, R. F. A. G., Koudstaal, P. J., Hofman, A., Franco, O. H., van der Lugt, A., & Ikram, M. A. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.05.1758 · Cited by 142 · cited 2×
“As demonstrated by another study, dementia occurred more frequently in patients with atherosclerotic calcifications in intra and extra-cranial arteries as opposed to coronary vessels [66].”
BackgroundLee, N., Heo, Y. J., Choi, S.-E., Jeon, J. Y., Han, S. J., Kim, D. J., Kang, Y., Lee, K. W., & Kim, H. J. (2021) · Journal of Immunology Research · doi:10.1155/2021/9944880 · Cited by 139 · cited 1×
“Empagliflozin was proven to mitigate inflammation by downregulation of the JAK2/STAT1 pathway in macrophages [89].”
BackgroundPerivascular Macrophages Limit Permeability
He, H., Mack, J. J., Güç, E., Warren, C. M., Squadrito, M. L., Kilarski, W. W., Baer, C., Freshman, R. D., McDonald, A. I., Ziyad, S., et al. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.307592 · Cited by 138 · cited 1×
“They also affect the permeability of the blood-brain barrier [91].”
BackgroundExpression of the Na+‐d‐Glucose Cotransporter SGLT1 in Neurons
Poppe, R., Karbach, U., Gambaryan, S., Wiesinger, H., Lutzenburg, M., Kraemer, M., Witte, O. W., & Koepsell, H. (1997) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1997.69010084.x · Cited by 134 · cited 1×
“SGLT1 inhibitors are present in the pyramidal cells of the brain cortex, Purkinje cerebellum cells, hippocampus pyramidal, and granular cells [20].”
BackgroundSuridjan, I., Pollock, B. G., Verhoeff, N. P. L. G., Voineskos, A. N., Chow, T., Rusjan, P. M., Lobaugh, N. J., Houle, S., Mulsant, B. H., & Mizrahi, R. (2015) · Molecular Psychiatry · doi:10.1038/mp.2015.1 · Cited by 132
Ganbaatar, B., Fukuda, D., Shinohara, M., Yagi, S., Kusunose, K., Yamada, H., Soeki, T., Hirata, K., & Sata, M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173040 · Cited by 130 · cited 3×
“Anti-inflammatory n/a Yes [35] Yes [36] Yes [37] No|n/a [38] Figure 1.”
Xu, L., Nagata, N., Chen, G., Nagashimada, M., Zhuge, F., Ni, Y., Sakai, Y., Kaneko, S., & Ota, T. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000783 · Cited by 128 · cited 1×
“Promoting M2 Macrophages Polarization n/a Yes [41] Yes [42] Yes [43] n/a”
BackgroundSafety of Sodium-Glucose Co-Transporter 2 Inhibitors
McGill, J. B., & Subramanian, S. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.10.029 · Cited by 127
Low BDNF is associated with cognitive deficits in patients with type 2 diabetes
Zhen, Y. F., Zhang, J., Liu, X. Y., Fang, H., Tian, L. B., Zhou, D. H., Kosten, T. R., & Zhang, X. Y. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2942-3 · Cited by 126 · cited 1×
“Interestingly, a significant decline of BDNF was observed in patients with T2DM, and it was associated with cognitive impairment, which was not observed in non-diabetic controls [64].”
BackgroundDual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
Bode, D., Semmler, L., Wakula, P., Hegemann, N., Primeßnig, U., Beindorff, N., Powell, D. R., Dahmen, R., Ruetten, H., Oeing, C. U., et al. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01208-z · Cited by 125 · cited 1×
“Oxidative Stress Reduction Yes [44] Yes [45] Yes [46] Yes [47] Yes [48]”
BackgroundIntracranial atherosclerosis and dementia: The Atherosclerosis Risk in Communities (ARIC) Study
Dearborn, J. L., Zhang, Y., Qiao, Y., Suri, M. F. K., Liu, L., Gottesman, R. F., Rawlings, A. M., Mosley, T. H., Alonso, Á., Knopman, D. S., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003837 · Cited by 112
Hasan, R., Lasker, S., Hasan, A., Zerin, F., Zamila, M., Parvez, F., Rahman, M. M., Khan, F., Subhan, N., & Alam, M. A. (2020) · Scientific Reports · doi:10.1038/s41598-020-71599-2 · Cited by 111 · cited 1×
“Oxidative Stress Reduction Yes [44] Yes [45] Yes [46] Yes [47] Yes [48]”
BackgroundZhang, Z., Li, X., Wang, Z.-H., Song, M., Yu, S. P., Kang, S. S., Liu, X., Zhang, Z., Xie, M., Liu, G., et al. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0286-z · Cited by 97 · cited 2×
“M1 polarized macrophages activate STAT-1, which is a proinflammatory transcription factor [87].”
BackgroundNguyen, T., Wen, S., Gong, M., Yuan, X., Xu, D., Wang, C., Jin, J., & Zhou, L. (2020) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s258593 · Cited by 97 · cited 5×
“It is possible that SGLT2 receptors also exert a cardioprotective effect through central mechanisms by directly influencing cardiovascular regulation and autonomic pathways, including the paraventricular nucleus of the hypothalamus, the nucleus of the solitary tract, and the periaqueductal gray [23].”
BackgroundInfluentialSGLT2 Inhibitors and Mechanisms of Hypertension
Briasoulis, A., Al Dhaybi, O., & Bakris, G. L. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0943-5 · Cited by 94
Hayden, M., Grant, D., Aroor, A., & DeMarco, V. (2019) · Brain Sciences · doi:10.3390/brainsci9030057 · Cited by 93 · cited 3×
“In a mouse model of T2DM, empagliflozin had a protective effect, involving remodeling prevention on the neurovascular unit, the blood-brain barrier, pericytes, astrocytes, microglia, and oligodendrocytes [49].”
BackgroundAbdel-latif, R. G., Rifaai, R. A., & Amin, E. F. (2020) · Archives of Pharmacal Research · doi:10.1007/s12272-020-01237-y · Cited by 92 · cited 3×
“In a study assessing cerebral ischemia/reperfusion damage in a rat model, empagliflozin, in a dose-dependant manner, reduced neuronal death, infarct size and ameliorated cognitive impairment via HIF-1α/VEGF signaling [50].”
BackgroundInfluentialSpotlight on ertugliflozin and its potential in the treatment of type 2 diabetes: evidence to date
Cinti, F., Moffa, S., Impronta, F., Cefalo, C. M. A., Sun, V. A., Sorice, G. P., Mezza, T., & Giaccari, A. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s114932 · Cited by 91 · cited 2×
“Sotagliflozin Canagliflozin Dapagliflozin Empagliflozin Ertugliflozin SGLT2 Selectivity over SGLT1 20 fold [28] 250 fold [28] 1200 fold [28] 2500 fold [28] 2500 fold [28] Brain/Serum Ratio n/a 0.”
BackgroundErdogan, M. A., Yusuf, D., Christy, J., Solmaz, V., Erdogan, A., Taskiran, E., & Erbas, O. (2018) · BMC Neurology · doi:10.1186/s12883-018-1086-4 · Cited by 87 · cited 3×
“Anti-epileptic Potential n/a n/a Yes [32] n/a /”
BackgroundInfluentialTau accumulation triggers STAT1‐dependent memory deficits by suppressing NMDA receptor expression
Li, X., Hong, X., Wang, Y., Zhang, S., Zhang, J., Li, X., Liu, Y., Sun, D., Feng, Q., Ye, J., et al. (2019) · The EMBO Reports · doi:10.15252/embr.201847202 · Cited by 81 · cited 1×
“In a murine model, depletion of STAT-1 activation significantly reduced synaptic dysfunction and cognitive impairment associated with Tau accumulation [88].”
BackgroundKerkhofs, D., van Hagen, B. T. J., Milanova, I. V., Schell, K. J., van Essen, H., Wijnands, E., Goossens, P., Blankesteijn, W. M., Unger, T., Prickaerts, J., et al. (2020) · Theranostics · doi:10.7150/thno.44394 · Cited by 80 · cited 1×
“In previous studies, depletion of perivascular macrophages prevented short-term memory impairment in a murine model [92].”
BackgroundCroteau, D., Luptak, I., Chambers, J. M., Hobai, I. A., Panagia, M., Pimentel, D. R., Siwik, D. A., Qin, F., & Colucci, W. S. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019995 · Cited by 76 · cited 1×
“Oxidative Stress Reduction Yes [44] Yes [45] Yes [46] Yes [47] Yes [48]”
BackgroundLee, S.-G., Lee, S.-J., Lee, J.-J., Kim, J.-S., Lee, O.-H., Kim, C.-K., Kim, D., Lee, Y.-H., Oh, J., Park, S., et al. (2020) · Korean Circulation Journal · doi:10.4070/kcj.2019.0296 · Cited by 75 · cited 2×
“SGLT2 inhibitors have been proven to strongly promote macrophage polarization towards M2 and thus alleviate inflammation and atherosclerosis (Table 1) [42].”
BackgroundZaibi, N. S., Li, P., & Xu, S. (2021) · PLoS ONE · doi:10.1371/journal.pone.0247234 · Cited by 75
Arafa, N. M. S., Ali, E. H. A., & Hassan, M. K. (2017) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2017.08.013 · Cited by 74 · cited 1×
“functions in the Y maze task and water maze task [62].”
MethodIrace, C., Casciaro, F., Scavelli, F. B., Oliverio, R., Cutruzzolà, A., Cortese, C., & Gnasso, A. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0695-y · Cited by 74 · cited 3×
“CIMT Regression n/a n/a Yes [33] Yes [34] /”
BackgroundRizvi, S., Shakil, S., Biswas, D., Shakil, S., Shaikh, S., Bagga, P., & Kamal, M. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/18715273113126660160 · Cited by 71
Shaikh, S., Rizvi, S. M. D., Shakil, S., Riyaz, S., Biswas, D., & Jahan, R. (2016) · Biotechnology and Applied Biochemistry · doi:10.1002/bab.1319 · Cited by 70 · cited 1×
“3 μM, respectively, so out of those two, only in the case of empagliflozin, brain concentration is enough to inhibit AChE (Table 1) [17,30,60].”
BackgroundFeinkohl, I., Keller, M., Robertson, C. M., Morling, J. R., Williamson, R. M., Nee, L. D., McLachlan, S., Sattar, N., Welsh, P., Reynolds, R. M., et al. (2013) · Diabetes Care · doi:10.2337/dc12-2241 · Cited by 69
Uddin, M. S., Rahman, M. A., Kabir, M. T., Behl, T., Mathew, B., Perveen, A., Barreto, G. E., Bin-Jumah, M. N., Abdel‐Daim, M. M., & Ashraf, G. M. (2020) · IUBMB Life · doi:10.1002/iub.2324 · Cited by 69 · cited 1×
“Continuous activation of mTOR causes endothelial cell dysfunction, which is not only a key point of atherosclerosis but also contributes to interruption in the blood-brain barrier [102].”
BackgroundAtherosclerosis in epilepsy: Its causes and implications
Hamed, S. A. (2014) · Epilepsy & Behavior · doi:10.1016/j.yebeh.2014.07.003 · Cited by 65 · cited 1×
“Interestingly, cognitive impairment shares the same risk factors as epilepsy and atherosclerosis, and commonly used anti-epileptic drugs such as phenytoin, carbamazepine, valproic acid are associated with increased cardiovascular risk [55].”
BackgroundPotential Therapeutic Effects of Sodium Glucose-linked Cotransporter 2 Inhibitors in Stroke
Hamed, F. A. A., & Elewa, H. F. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.09.008 · Cited by 63
Role of DPP-4 and SGLT2 Inhibitors Connected to Alzheimer Disease in Type 2 Diabetes Mellitus
Sim, A. Y., Barua, S., Kim, J. Y., Lee, Y.-H., & Lee, J. E. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.708547 · Cited by 62
Canagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
Behnammanesh, G., Durante, Z. E., Peyton, K. J., Martinez-Lemus, L. A., Brown, S. M., Bender, S. B., & Durante, W. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00362 · Cited by 61 · cited 9×
“SGLT2 inhibitors can possibly bring benefits in patients with Alzheimer’s Disease using the abovementioned mechanisms, including not only anti-inflammatory, antioxidative or atheroprotective effects, but also direct neuroprotective effects including BDNF increase and AChE inhibition.”
BackgroundInfluentialChiba, Y., Sugiyama, Y., Nishi, N., Nonaka, W., Murakami, R., & Ueno, M. (2020) · Neuropathology · doi:10.1111/neup.12665 · Cited by 59 · cited 1×
“There is in vivo evidence for the expression of SGLT2 protein in choroid plexus epithelial cells and ependymal cells of the human brain [56].”
BackgroundESTERLINE, R. L., Oscarsson, J., & Burns, J. M. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.018 · Cited by 54
Lin, F., Song, C., Zeng, Y., Li, Y., Li, H., Liu, B., Dai, M., & Pan, P. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106969 · Cited by 53 · cited 1×
“Promoting M2 Macrophages Polarization n/a Yes [41] Yes [42] Yes [43] n/a”
BackgroundDysfunction of the neurovascular unit in diabetes-related neurodegeneration
Yan, C., Zhou, Y., Chen, Q., Luo, Y., Zhang, J. H., Huang, H., & Shao, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110656 · Cited by 49
Stanciu, G. D., Rusu, R. N., Bild, V., Filipiuc, L. E., Tamba, B.-I., & Ababei, D. C. (2021) · Biomedicines · doi:10.3390/biomedicines9050576 · Cited by 47
Liu, H., Sridhar, V. S., Lovblom, L. E., Lytvyn, Y., Burger, D. E., Burns, K. D., Brinc, D., Lawler, P. R., & Cherney, D. Z. I. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.05.022 · Cited by 47 · cited 2×
“Anti-inflammatory n/a Yes [35] Yes [36] Yes [37] No|n/a [38] Figure 1.”
Bi, C., Fu, Y., & Li, B. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109569 · Cited by 46 · cited 2×
“In the same study, supplementation of BDNF in mice significantly reduced atherosclerotic lesions [65].”
BackgroundShakil, S. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26036 · Cited by 45 · cited 1×
“6μM [29] The most potent, even called a dual inhibitor Ki 0.”
BackgroundOerter, S., Förster, C., & Bohnert, M. (2019) · International Journal of Legal Medicine · doi:10.1007/s00414-018-1893-6 · Cited by 43 · cited 1×
“An immunoblotting study of post-mortem human brain tissue showed a significant increase in SGLT1 and SGLT2 expression following brain injury [25].”
BackgroundSkike, C. E. V., & Galván, V. (2018) · Gerontology · doi:10.1159/000485381 · Cited by 42 · cited 1×
“Unrestrained mTOR up-regulation has also been linked to tau and amyloid β hyperphosphorylation and aggregation in Alzheimer’s disease [103].”
BackgroundArchana Gaur, T., Pal, G. K., Ananthnarayanan, P. H., Pal, P., & Ijomone, O. M. (2014) · Annals of Neurosciences · doi:10.5214/ans.0972.7531.210306 · Cited by 37 · cited 1×
“Interestingly, the brain locations where SGLTs are present have been proven to be responsible for learning processes, food intake, energy and glucose homeostasis, and central cardiovascular and autonomic regulation [23,24].”
BackgroundRevisiting atherosclerosis and dementia
Iadecola, C. (2020) · Nature Neuroscience · doi:10.1038/s41593-020-0626-6 · Cited by 32 · cited 1×
“Additionally, atherosclerosis is an important factor leading to cognitive impairment in the elderly via several mechanisms such as ischemia and a direct molecular link [2,3].”
BackgroundPearson, A., Ajoy, R., Crynen, G. C., Reed, J. M., Algamal, M., MULLAN, M. J., Purohit, D. P., Crawford, F., & Ojo, J. O. (2020) · BMC Neurology · doi:10.1186/s12883-020-01849-3 · Cited by 29 · cited 1×
“This is crucial information indicating that SGLT2 may have an influence on the composition of the cerebrospinal fluid (CSF), whose role in the pathology of neurodegenerative disorders provides a new direction for research and requires further investigation [57].”
BackgroundLiu, J., Zhu, Y., Wu, Y., Liu, Y., Teng, Z., & Hao, Y. (2017) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s124386 · Cited by 22
Sodium glucose co-transporter inhibitors—A new class of old drugs
Malhotra, P., Malhotra, A., Kudyar, S., Gupta, A., & Kudyar, R. (2015) · International Journal of Applied and Basic Medical Research · doi:10.4103/2229-516x.165363 · Cited by 21
Sebastiani, A., Greve, F., Gölz, C., Förster, C. Y., Koepsell, H., & Thal, S. C. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14551 · Cited by 21 · cited 1×
“Results of a study performed in a murine model suggest that, after a brain injury, SGLT1 blockage may bring beneficial effects with regard to the area of the brain lesions, the volume of damaged tissue, edema, and motoric disability [26].”
BackgroundYamazaki, Y., Harada, S., Wada, T., Hagiwara, T., Yoshida, S., & Tokuyama, S. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.02.007 · Cited by 19
Inaba, Y., Hashiuchi, E., Watanabe, H., Kimura, K., Sato, M., Kobayashi, M., Matsumoto, M., Kitamura, T., Kasuga, M., & Inoue, H. (2019) · Endocrinology · doi:10.1210/en.2019-00422 · Cited by 18
Ishida, N., Saito, M., Sato, S., Koepsell, H., Taira, E., & Hirose, M. (2020) · Neuroscience Letters · doi:10.1016/j.neulet.2020.134929 · Cited by 13
Shaikh, S., Rizvi, S. M., Suhail, T., Shakil, S., Abuzenadah, A., Anis, R., Naaz, D., Dallol, A., Haneef, M., Ahmad, A., et al. (2016) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527315666161003125752 · Cited by 10 · cited 1×
“3 μM, respectively, so out of those two, only in the case of empagliflozin, brain concentration is enough to inhibit AChE (Table 1) [17,30,60].”
BackgroundOxidative Stress in Vascular Pathophysiology: Still Much to Learn
Zalba, G. (2021) · Antioxidants · doi:10.3390/antiox10050673 · Cited by 5
Moellmann, J., Mann, P., Krueger, K., Klinkhammer, B. M., Boor, P., Marx, N., & Lehrke, M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab724.3289 · Cited by 5 · cited 1×
“Reduced mTOR Signaling n/a Yes [51] Yes [51] Yes [52] Yes [53]”
BackgroundAkhanlı, P., Hepşen, S., Emre, A. I., Düğer, H., Bostan, H., Kızılgül, M., Uçan, B., & Çakal, E. (2020) · Endocrine Abstracts · doi:10.1530/endoabs.70.aep816 · Cited by 1
Research works printed but not linked: 1
- Esterline, R., Oscarsson, J., and Burns, J. (2020). International Review of Neurobiology, Elsevier Inc.. [1st ed.].
Cited by
Wang, W., Wang, Q., Qi, X., Gurney, M., Perry, G., Volkow, N. D., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Alzheimer's & Dementia · doi:10.1002/alz.14313 · Cited by 180
Mone, P., Lombardi, A., Gambardella, J., Pansini, A., Macina, G., Morgante, M., Frullone, S., & Santulli, G. (2022) · Diabetes Care · doi:10.2337/dc21-2434 · Cited by 151
Inflammatory Mechanisms of Diabetes and Its Vascular Complications
Nedosugova, L. V., Markina, Y. V., Бочкарева, Л. А., Кузина, И. А., Petunina, N. A., Yudina, I. Y., & Kirichenko, T. V. (2022) · Biomedicines · doi:10.3390/biomedicines10051168 · Cited by 157
GLP-1RA and SGLT2i Medications for Type 2 Diabetes and Alzheimer Disease and Related Dementias
Tang, H., Donahoo, W. T., DeKosky, S. T., Lee, Y. A., Kotecha, P., Svensson, M., Bian, J., & Guo, J. S. (2025) · JAMA Neurology · doi:10.1001/jamaneurol.2025.0353 · Cited by 116
Mei, J., Li, Y., Niu, L., Liang, R., Tang, M., Cai, Q., Xu, J., Zhang, D., Yin, X., Liu, X., et al. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00431-y · Cited by 98
“Neuroinflammation is closely related to cognitive deficits [5].”
Background
Metadata
- Authors
- Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P.
- Affiliations
- Medical University of Lodz (PL)
- Laboratory of Tissue Immunopharmacology, Department of Internal Diseases and Clinical Pharmacology, Medical University of Lodz, Kniaziewicza 1/5, 91-347 Lodz, Poland
- Corresponding author
- Broncel, Marlena
- Venue
- Molecules
- Publisher
- MDPI AG
- Published
- 2021-11-28
- Volume
- 26
- Issue
- 23
- Pages
- 7213
- ISSN
- 1420-3049 (ISSN-L)
- PMC
- PMC8659196
- OpenAlex
- W3214770882
- Semantic Scholar
- d4fddd52e53127993c142ff6d31526f815eb1c00
- Cited by
- 304
- References
- 124
- Citations by year
- 2026: 66 · 2025: 92 · 2024: 71 · 2023: 50 · 2022: 25
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Molecules (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Neurology › Neuroprotection in Cerebral Ischemia
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Neurology › Neurological Disease Mechanisms and Treatments
- Keywords
- SGLT2 inhibitors, neuroprotection, type 2 diabetes, cognitive impairment, cardiovascular disease, anti-inflammatory activity, NLRP3 inflammasome, cerebral blood flow, neurovascular unit, blood-brain barrier, acetylcholinesterase inhibition, brain-derived neurotrophic factor, atherosclerosis
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Animals, Brain, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Neuroprotective Agents, Atherosclerosis, Sodium-Glucose Transporter 2, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-04, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-04 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.